CD22-CAR therapy shows activity in rel/ref B-ALL

Print Friendly, PDF & Email


Micrograph showing B-ALL
Researchers say they have reported the first results demonstrating clinical activity of a CD22-directed chimeric antigen receptor (CAR) T-cell therapy in B-cell acute lymphoblastic leukemia (B-ALL). The team conducted a phase 1 study of the therapy in 21 children and adults with relapsed/refractory B-ALL. Twelve patients achieved a complete response... [Read Article]
Print Friendly, PDF & Email

Rigosertib produces better OS in MDS than tAML

Print Friendly, PDF & Email


Micrograph showing
myelodysplastic syndrome
Rigosertib has demonstrated activity and tolerability in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia transformed from MDS (tAML), according to researchers. In a phase 1/2 study, rigosertib produced responses in a quarter of MDS/tAML patients and enabled stable disease in another quarter. Overall survival (OS) was about... [Read Article]
Print Friendly, PDF & Email

FDA approves generic clofarabine

Print Friendly, PDF & Email


Micrograph showing
acute lymphoblastic leukemia
The US Food and Drug Administration (FDA) has approved Dr. Reddy’s Laboratories Ltd.’s Clofarabine Injection, a therapeutic equivalent generic version of Clolar® (clofarabine) Injection. The generic drug is now approved to treat patients age 1 to 21 who have relapsed or refractory acute lymphoblastic leukemia and have received at... [Read Article]
Print Friendly, PDF & Email

Generic azacitidine approved in Canada

Print Friendly, PDF & Email


Micrograph showing
acute myeloid leukemia
Health Canada has approved Dr. Reddy’s Laboratories Ltd.’s Azacitidine for Injection 100 mg/vial, a bioequivalent generic version of VIDAZA® (azacitidine for injection). The generic drug is approved for the same indications as VIDAZA®. This includes treating adults with intermediate-2 or high-risk myelodysplastic syndromes (according to the International... [Read Article]
Print Friendly, PDF & Email